U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C67H103N5O19
Molecular Weight 1282.5568
Optical Activity UNSPECIFIED
Defined Stereocenters 18 / 19
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMCIPATRICIN

SMILES

[H][C@]12C[C@@H](O[C@]3([H])O[C@H](C)[C@@H](O)[C@H](NC(=O)CN(C)C)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@]([H])(OC(=O)C[C@H](O)CC(=O)C[C@H](O)C[C@H](O)C[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(=O)NCCN(C)C)O2)[C@@H](C)CCC(O)CC(=O)C4=CC=C(NC)C=C4

InChI

InChIKey=UJGVOBAKMNJQEV-LYLBHANESA-N
InChI=1S/C67H103N5O19/c1-42-21-19-17-15-13-11-9-10-12-14-16-18-20-22-54(89-66-63(85)61(62(84)44(3)88-66)70-58(82)41-72(7)8)38-57-60(65(86)69-29-30-71(5)6)56(81)40-67(87,91-57)39-53(79)35-51(77)33-49(75)31-48(74)32-50(76)34-52(78)37-59(83)90-64(42)43(2)23-28-47(73)36-55(80)45-24-26-46(68-4)27-25-45/h9-22,24-27,42-44,47-49,51-54,56-57,60-64,66,68,73-75,77-79,81,84-85,87H,23,28-41H2,1-8H3,(H,69,86)(H,70,82)/b10-9+,13-11+,14-12+,17-15+,18-16+,21-19+,22-20+/t42-,43-,44+,47?,48+,49-,51-,52+,53-,54-,56-,57-,60+,61-,62+,63-,64-,66-,67+/m0/s1

HIDE SMILES / InChI
SPK-843 is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of systemic fungal infections. In preclinical models, SPK-843 shows in vitro inhibitory activity comparable to or better than that of Amphotericin B against Candida spp., Cryptococcus neoformans, and Aspergillus spp. SPK-843 exhibits dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) and liposomal amphotericin B.

Approval Year

PubMed

PubMed

TitleDatePubMed
SPK-843 (Aparts/Kaken).
2005 Aug
Patents

Patents

Sample Use Guides

0.5 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
Route of Administration: Intravenous
Name Type Language
AMCIPATRICIN
INN  
Official Name English
amcipatricin [INN]
Common Name English
N3'-((DIMETHYLAMINO)ACETYL)PARTRICIN-A 2-(DIMETHYLAMINO)ETHYLAMIDE: (1R,3S,5S,7R,9R,13R,17R,18S,19E,21E,23Z,25Z,27E,29E,31E,33R, 35S,36R,37S)-33-((3,6-DIDEOXY-3-(2-(DIMETHYLAMINO)ACETAMIDO)-.BETA.-DMANNOPYRANOSYL) OXY)-N-(2-(DIMETHYLAMINO)ETHYL)-1,3,5,7,
Systematic Name English
CANDICIDIN D, 18-DECARBOXY-40-DEMETHYL-3,7-DIDEOXO-N3'-((DIMETHYLAMINO)ACETYL)-18-(((2-(DIMETHYLAMINO)ETHYL)AMINO)CARBONYL)-3,7-DIHYDROXY-N47-METHYL-5-OXO-, CYCLIC 15,19-HEMIACETAL
Systematic Name English
SPA-S-752
Code English
Code System Code Type Description
SMS_ID
300000040286
Created by admin on Sat Dec 16 14:44:22 GMT 2023 , Edited by admin on Sat Dec 16 14:44:22 GMT 2023
PRIMARY
NCI_THESAURUS
C174893
Created by admin on Sat Dec 16 14:44:22 GMT 2023 , Edited by admin on Sat Dec 16 14:44:22 GMT 2023
PRIMARY
INN
10912
Created by admin on Sat Dec 16 14:44:22 GMT 2023 , Edited by admin on Sat Dec 16 14:44:22 GMT 2023
PRIMARY
CAS
143483-67-4
Created by admin on Sat Dec 16 14:44:22 GMT 2023 , Edited by admin on Sat Dec 16 14:44:22 GMT 2023
PRIMARY
PUBCHEM
11963628
Created by admin on Sat Dec 16 14:44:22 GMT 2023 , Edited by admin on Sat Dec 16 14:44:22 GMT 2023
PRIMARY
FDA UNII
QO0X1DPX2D
Created by admin on Sat Dec 16 14:44:22 GMT 2023 , Edited by admin on Sat Dec 16 14:44:22 GMT 2023
PRIMARY